EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Therapeutic Effects of Glucagon-like Peptide-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: A Systematic Review

Dina Mahoon iD, Fares Kellany iD, Imad Khan iD, Somieya Khan iD, Alexandra E Butler iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27125618 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Dina Mahoon und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Royal College of Surgeons in Ireland-Medical University of Bahrain, Busaiteen 15503, Bahrain. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-alcoholic fatty liver disease (NAFLD), now increasingly termed metabolic dysfunction-associated steatotic liver disease (MASLD), is a growing cause of chronic liver disease with limited treatment options. Glucagon-like peptide-1 (GLP-1) receptor agonists, approved for type 2 diabetes and obesity, possess metabolic effects that may render them suitable for treating NAFLD and metabolic dysfunction-associated steatohepatitis (MASH). To evaluate the therapeutic effects of GLP-1 receptor agonists in adults with NAFLD, non-alcoholic steatohepatitis (NASH), MASLD, or MASH. PubMed, Scopus, Embase, and the Cochrane Library were systematically searched using keywords related to NAFLD and GLP-1 receptor agonists. Given heterogeneity in populations, designs, and outcomes, findings were synthesized narratively. The review is registered with PROSPERO (CRD420261337353). Twelve studies met the inclusion criteria. The most consistent outcome was a reduction in hepatic fat, seen with semaglutide, liraglutide, dulaglutide, and beinaglutide. Improvements in liver enzymes, particularly alanine aminotransferase, were less consistent and best regarded as supportive rather than definitive evidence of histological improvement. Histological benefits were strongest for steatohepatitis resolution in non-cirrhotic MASH. Fibrosis findings were mixed, with the greatest benefit in F2–F3 MASH and limited improvement in established cirrhosis. GLP-1 receptor agonists were generally well tolerated, with gastrointestinal symptoms the most common adverse effects. GLP-1 receptor agonists show promising liver-related benefits in NAFLD and MASH, particularly in obesity, type 2 diabetes, or earlier-stage disease. Their effects on advanced fibrosis and long-term outcomes remain uncertain, warranting larger, longer-term studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseGlucagon-Like Peptide-1 Receptor AgonistsHumansSemaglutideGlucagon-Like PeptidesGlucagon-Like Peptide-1 ReceptorLiraglutideAnimalsLiverImmunoglobulin Fc FragmentsRecombinant Fusion Proteins

Stichwörter der Autor:innen

GLP-1 receptor agonistsMASLDNAFLDliver fatliver fibrosis

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsSemaglutideGlucagon-Like PeptidesGlucagon-Like Peptide-1 ReceptorLiraglutidedulaglutideImmunoglobulin Fc FragmentsRecombinant Fusion Proteins

Autor:innen und Institutionen

  • School of Medicine, Royal College of Surgeons in Ireland-Medical University of Bahrain, Busaiteen 15503, Bahrain.
  • Research Department, Royal College of Surgeons in Ireland-Medical University of Bahrain, Busaiteen 15503, Bahrain.

ORCID-Profile: Dina Mahoon, Fares Kellany, Imad Khan, Somieya Khan, Alexandra E Butler

Zitieren

APA

Mahoon, D., Kellany, F., Khan, I., Khan, S., & Butler, A. E. (2026). Therapeutic Effects of Glucagon-like Peptide-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: A Systematic Review. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27125618

Vancouver

Mahoon D, Kellany F, Khan I, Khan S, Butler AE. Therapeutic Effects of Glucagon-like Peptide-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: A Systematic Review. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27125618

BibTeX
@article{Mahoon2026,
  author = {Mahoon, Dina and Kellany, Fares and Khan, Imad and Khan, Somieya and Butler, Alexandra E},
  title = {Therapeutic Effects of Glucagon-like Peptide-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: A Systematic Review},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27125618}
}
Kostenlos starten →